2023 World Conference on Lung Cancer (Posters)-EP12.02. Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC

EP12.02. Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to compare the efficacy of entrectinib and crizotinib as first-line therapies for ROS1 fusion-positive advanced non-small cell lung cancer (NSCLC) in Asian patients. The authors conducted an indirect comparison using matching-adjusted indirect comparison (MAIC) methodology. Individual patient data from entrectinib trials and aggregated data from a crizotinib trial were analyzed. Baseline characteristics were matched between the two populations using propensity score modeling, and outcomes including progression-free survival (PFS) and overall survival (OS) were evaluated.<br /><br />The analysis included 52 entrectinib and 127 crizotinib-treated Asian ROS1 NSCLC patients. After matching, the median PFS was 39.4 months in the entrectinib group compared to 15.9 months in the crizotinib group. The hazard ratio (HR) for PFS between the two groups was 0.688, indicating a trend towards better outcomes with entrectinib. Median OS was not reached in the entrectinib group and was 44.2 months in the crizotinib group, with an HR of 0.662.<br /><br />The results suggest that entrectinib may provide better survival outcomes compared to crizotinib in Asian patients with ROS1 NSCLC. These findings may assist healthcare providers in making informed treatment decisions. However, it is important to note that this study had limitations, including the small effective sample size of the entrectinib trials and potential hidden confounders or effect modifiers.<br /><br />In conclusion, this MAIC analysis provides comparative evidence on the efficacy of entrectinib and crizotinib in Asian patients with ROS1 NSCLC. The results suggest a trend towards better outcomes with entrectinib, but further research with larger sample sizes and consideration of potential confounding factors is needed.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

entrectinib

crizotinib

first-line therapies

ROS1 fusion-positive

advanced non-small cell lung cancer

NSCLC

Asian patients

matching-adjusted indirect comparison

progression-free survival

overall survival